1. Signaling Pathways
  2. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  3. EGFR
  4. EGFR Inhibitors

EGFR Inhibitors

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

EGFR Inhibitors, Antagonists & Activators
Product Name EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4 Purity
Osimertinib
EGFRL858R, IC50: 12 nM (Enzyme assays)
EGFRL858R/T790M, IC50: 1 nM (Enzyme assays)
      99.95%
Erlotinib
EGFR, IC50: 2 nM (Cell Free Assay)
      99.99%
NSC 228155
EGFR
      >98.0%
Gefitinib-based PROTAC 3
EGFR, DC50: 11.7 nM (HCC827(exon 19 del) cells)
EGFR, DC50: 22.3 nM (H3255 (L858R mutantion) cells)
      99.98%
Cetuximab
Soluble EGFR, Kd: 0.201 nM
EGFR, Kd: 0.147 nM (Fixed A431 cells)
      99.70%
Genistein
EGFR, IC50: 0.6 μM (Cell Assay)
      99.68%
Neratinib
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
    98.84%
Dacomitinib
EGFR, IC50: 6 nM
ErbB2, IC50: 45.7 nM
 
ErbB4, IC50: 73.7 nM
99.83%
Erlotinib Hydrochloride
EGFR, IC50: 2 nM
      99.99%
AG-1478
EGFR, IC50: 3 nM
      99.74%
Osimertinib mesylate
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 12 nM
      99.96%
Sapitinib
EGFR, IC50: 4 nM
ErbB2, IC50: 3 nM
HER3, IC50: 4 nM
  99.99%
Pyrotinib
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    98.84%
TAS6417
EGFR, IC50: 1.1-8.0 nM
      99.55%
BMS-690514
EGFR, IC50: 5 nM
HER2, IC50: 20 nM
 
HER4, IC50: 60 nM
99.37%
Mubritinib  
HER2, IC50: 6 nM
    99.97%
Gefitinib hydrochloride
EGFR
      99.80%
Olmutinib
EGFRExon 19 deletion, IC50: 9.2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 10 nM (Cell Assay)
      99.99%
Icotinib
EGFR, IC50: 5 nM
      99.80%
Canertinib dihydrochloride
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    98.51%
Pelitinib
EGFR, IC50: 38.5 nM
      98.18%
Afatinib dimaleate
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
    99.31%
Tyrphostin 23
EGFR, IC50: 35 μM (Cell Assay)
EGFR, Ki: 11 μM
      98.04%
AZ-5104
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 1 nM
EGFRL861Q, IC50: 6 nM
EGFR, IC50: 25 nM
   
ErbB4, IC50: 7 nM
99.70%
Rociletinib
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      99.08%
Varlitinib
HER1, IC50: 7 nM
HER2, IC50: 2 nM
 
HER4, IC50: 4 nM
>98.0%
PD158780
EGFR, IC50: 8 μM (Cell Assay)
ErbB2, IC50: 49 nM (Cell Assay)
ErbB3, IC50: 52 nM (Cell Assay)
ErbB4, IC50: 52 nM (Cell Assay)
98.04%
Lazertinib
EGFRT790M
      99.25%
Falnidamol
EGFR, IC50: 3 nM
      98.07%
CUDC-101
EGFR, IC50: 2.4 nM
HER2, IC50: 15.7 nM
    99.59%
Butein
EGFR
      99.95%
CP-724714  
ErbB2, IC50: 10 nM
    99.62%
Tesevatinib
EGFR, IC50: 0.3 nM
ErbB2, IC50: 16 nM
    99.21%
EAI045
EGFR, IC50: 1.9 μM
EGFRL858R, IC50: 0.019 μM
EGFRT790M, IC50: 0.19 μM
EGFRL858R/T790M, IC50: 0.002 μM
      99.33%
Lifirafenib
EGFR, IC50: 29 nM
EGFRL858R/T790M, IC50: 495 nM
      98.00%
PD168393
EGFR, IC50: 0.7 nM
      98.87%
PD153035
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      98.66%
Tarloxotinib bromide  
EGFR/HER2
    98.97%
Avitinib maleate
EGFR, IC50: 7.68 nM
      >98.0%
AEE788
EGFR, IC50: 2 nM
ErbB2, IC50: 6 nM
    99.91%
Nazartinib
EGFRL858R/T790M, Ki: 31 nM
      99.57%
WZ4002
EGFRL858R, IC50: 2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 8 nM (Cell Assay)
EGFRE746_A750, IC50: 3 nM (Cell Assay)
EGFRE746_A750/T790M, IC50: 2 nM (Cell Assay)
      98.67%
Icotinib Hydrochloride
EGFR, IC50: 5 nM
      99.99%
TAK-285
EGFR, IC50: 23 nM
HER2, IC50: 17 nM
    99.16%
TAS0728
EGFR, IC50: 65 nM
HER2, IC50: 13 nM
Human HER2, IC50: 36 nM
 
HER4, IC50: 8.5 nM
99.15%
Canertinib
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    99.10%
WHI-P154
EGFR, IC50: 4 nM
      98.60%
AST2818 mesylate
EGFR
      99.99%
Osimertinib dimesylate
EGFRL858R, IC50: 12 nM
EGFRL858R/T790M, IC50: 1 nM
      99.96%
Naquotinib mesylate
EGFRL858R/T790M
EGFRL858R
EGFRExon 19 deletion
EGFRExon 19 deletion/T790M
EGFR, IC50: 230 nM
      98.19%
Daphnetin
EGFR, IC50: 7.67 μM
      99.55%
Allitinib tosylate
EGFR, IC50: 0.5 nM
ErbB2, IC50: 3 nM
    99.23%
AV-412 free base
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.51 nM
EGFRL858R/T790M, IC50: 2.3 nM
EGFRT790M, IC50: 0.79 nM
ErbB2, IC50: 19 nM
    98.49%
RG14620
EGFR, IC50: 3 μM (Cell Assay)
      98.98%
CNX-2006
EGFRT790M, IC50: 20 nM
      98.06%
AV-412
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.5 nM
EGFRT790M, IC50: 0.79 nM
EGFRL858R/T790M, IC50: 2.3 nM
ErbB2, IC50: 19 nM
    99.17%
NRC-2694
EGFR
      98.40%
Pyrotinib dimaleate
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    98.60%
Epertinib
EGFR, IC50: 1.48 nM
HER2, IC50: 2.49 nM
 
HER4, IC50: 7.15 nM
>98.0%
MTX-211
EGFR
      98.65%
Chrysophanol
EGFR
      99.63%
Rociletinib hydrobromide
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      97.45%
PD153035 Hydrochloride
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      98.62%
CL-387785
EGFR, IC50: 370 pM
      97.06%
Naquotinib
EGFR, IC50: 230 nM
     
AG 555
EGFR
      >98.0%
Tyrphostin AG 528
EGFR, IC50: 4.9 μM
ErbB2, IC50: 2.1 μM
    >98.0%
Mutant EGFR inhibitor
EGFRL858R
EGFRExon 19 deletion
EGFRT790M
      98.94%
WHI-P180
EGFR, IC50: 4 μM
      99.76%
Nazartinib mesylate
EGFRL858R/T790M, Ki: 31 nM
     
Mutated EGFR-IN-1
EGFRL858R
EGFRExon 19 deletion/T790M
EGFRT790M
      99.88%
ZD-4190
EGFR
      99.20%
TX1-85-1    
ErbB3, IC50: 23 nM
  >98.0%
(E)-AG 99
EGFR
      99.41%
EGFR-IN-7
EGFR (WT), IC50: 7.92 nM
EGFR (C797S/T790M/L858R), IC50: 0.218 nM
     
Mutated EGFR-IN-2
EGFR (L858R/T790M), IC50: <1 nM
     
CHMFL-EGFR-202
EGFRT790M, IC50: 5.3 nM
EGFR, IC50: 8.3 nM
ErbB2, IC50: 8.1 nM
 
ErbB4, IC50: 3.2 nM
EGFR-IN-5
EGFR, IC50: 10.4 nM
EGFRL858R, IC50: 1.1 nM
EGFRL858R/T790M, IC50: 34 nM
EGFRL858R/T790M/C797S, IC50: 7.2 nM
     
Astragaloside VI
EGFR
      >98.0%
WHI-P180 hydrochloride
EGFR, IC50: 4 μM
     
Erlotinib mesylate
EGFR, IC50: 2 nM
     
BGB-102
EGFR, IC50: 9.6 nM
HER2, IC50: 18 nM
 
HER4, IC50: 40.3 nM
Allitinib
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM